ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2024 - 2026)

ARS Pharmaceuticals (SPRY) has 3 years of Goodwill & Intangibles data on file, last reported at $14.2 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles rose 5547.81% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.2 million (up 5547.81% YoY), and the FY2025 full-year result was $14.5 million, up 96.07% from the prior year.
• Goodwill & Intangibles slipped to $14.2 million in Q1 2026, from $14.5 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $14.5 million in Q4 2025 to a low of $125000.0 in Q3 2025.
• A 3-year average of $8.2 million and a median of $10.2 million in 2024 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles surged 96.07% in 2025 and surged 5547.81% in 2026, its largest moves.
• Tracing SPRY's Goodwill & Intangibles over 3 years: stood at $7.4 million in 2024, then surged by 96.07% to $14.5 million in 2025, then decreased by 1.91% to $14.2 million in 2026.
• Business Quant data shows SPRY's Goodwill & Intangibles at $14.2 million in Q1 2026, $14.5 million in Q4 2025, and $125000.0 in Q3 2025.